TuisFGEN ⢠NASDAQ
add
Kyntra Bio Inc
Vorige sluiting
$9,07
Dagwisseling
$9,02 - $9,38
Jaarwisseling
$9,02 - $9,70
Markkapitalisasie
36,98Ā m USD
Gemiddelde volume
34,63Ā k
P/V-verhouding
0,17
Dividend-opbrengs
-
PrimĆŖre beurs
NASDAQ
Marknuus
.INX
0,064%
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 1,08Ā m | 774,80% |
Bedryfskoste | 5,30Ā m | -43,44% |
Netto inkomste | 200,64Ā m | 1Ā 274,41% |
Netto winsgrens | 18,65Ā k | 234,25% |
Wins per aandeel | 49,61 | 13Ā 491,78% |
EBITDA | -5,18Ā m | 81,77% |
Effektiewe belastingkoers | ā | ā |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 117,98Ā m | -9,94% |
Totale bates | 137,01Ā m | -48,18% |
Totale aanspreeklikheid | 119,53Ā m | -74,36% |
Totale ekwiteit | 17,48Ā m | ā |
Uitstaande aandele | 4,05Ā m | ā |
Prys om te bespreek | -2,15 | ā |
Opbrengs op bates | -8,52% | ā |
Opbrengs op kapitaal | 52,71% | ā |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 200,64Ā m | 1Ā 274,41% |
Kontant van bedrywe | -1,85Ā m | 77,95% |
Kontant van beleggings | 87,16Ā m | 11Ā 444,37% |
Kontant van finansiering | -85,92Ā m | -67Ā 551,18% |
Netto kontantverandering | -1,87Ā m | 80,78% |
Beskikbare kontantvloei | 72,84Ā m | 1Ā 077,84% |
Meer oor
FibroGen, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018ā19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2025, FibroGen was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
Gestig
01 Jan. 1993
Webwerf
Werknemers
225